甲状腺癌患者血清IL-17、IL-35、SIL-2R表达水平及其临床意义

目的:探讨甲状腺癌患者血清白细胞介素-17(IL-17)、白细胞介素-35(IL-35)及可溶性白介素-2受体(SIL-2R)水平及其对甲状腺癌诊断与病情评估的临床价值。方法:选取我院2015年6月~2016年12月收治的甲状腺腺瘤患者38例、甲状腺癌患者49例为研究对象,另选取同期于我院体检中心接受体检的52例健康体检者为对照组。采用酶联免疫吸附法(ELISA)检测和比较其血清IL-17、IL-35、SIL-2R水平,并分析甲状腺癌患者血清IL-17、IL-35、SIL-2R水平与其年龄、病程、病理分期的相关性。结果:甲状腺腺瘤组血清IL-17、IL-35、SIL-2R水平与对照组比较差异均无统计学意义(P0.05)。甲状腺癌组血清IL-35水平显著低于甲状腺腺瘤组和对照组(P0.01),血清IL-17、SIL-2R水平均显著高于甲状腺瘤组和对照组(P0.01)。血清IL-17、SIL-2R水平随甲状腺癌分化程度的降低而升高,血清IL-35水平随甲状腺癌分化程度的降低而降低(P0.01)。血清IL-17、SIL-2R水平随甲状腺癌病理分期的增加而升高,血清IL-35水平随甲状腺癌病理分期的增加而降低(P0.01)。血清IL-17、SIL-2R水平与甲状腺癌病理分期均呈显著正相关(r=0.432、0.439,P均0.05)。血清IL-35水平与甲状腺癌病理分期呈显著负相关(r=-0.602,P0.05)。血清IL-17与IL-35呈显著负相关(r=-0.323,P0.05),IL-17与SIL-2R呈显著正相关(r=0.429,P0.05),IL-35与SIL-2R呈显著负相关(r=-0.415,P0.05)。结论:甲状腺癌患者的血清IL-17、SIL-2R水平均显著上调,IL-35水平显著下调,其对甲状腺癌的早期诊断、病情评估均具有重要参考价值。

Expressions and Clinical Significance of Serum IL-17, IL-35 and SIL-2R in Patients with Thyroid Cancer

ABSTRACT Objective: To explore the levels and clinical significances of interleukin-17 (IL-17), interleukin-35 (IL-35) and soluble interleukin-2 receptor (SIL-2R) for the diagnosis and disease severity assessment of patients with thyroid cancer. Methods: 38 cases of patients with thyroid adenoma and 49 cases with thyroid cancer in our hospital from June 2015 to December 2016 were selected as research objectives, 52 healthy cases who were admitted to the physical examination center in our hospital were selected as the control group. The serum IL-17, IL-35 and SIL-2R levels were measured by enzyme-linked immunosorbent assay (ELISA). The levels of serum IL-17, IL-35 and SIL-2R of patients with thyroid cancer were analyzed by correlation with the age, course of disease and pathological staging. Results: No statistical difference was found in the serum IL-17, IL-35 and SIL-26 levels between thyroid adenoma group and control group (P>0.05). The serum IL-35 level of thyroid cancer group was significantly lower than that of the thyroid adenoma group and control group (P<0.01), and the serum IL-17, SIL-2R levels were significantly higher than those in the thyroid adenoma group and control group (P<0.01). The serum IL-17, SIL-2R levels were increased with the differentiation degree of thyroid cancer, the serum IL-25 level was decreased with the differentiation degree of thyroid cancer (P<0.01). The serum IL-17, SIL-2R levels were increased with the pathological staging of thyroid cancerg, the serum IL-35 level was decreased with the pathological staging of thyroid cancer(P<0.01). There was a significant positive correlation between serum IL-17, SIL-2R levels and pathological staging of thyroid cancer (r=0.432, 0.439, all P<0.05). There was a significant negative correlation between serum IL-35 level and pathological staging of thyroid cancer (r=-0.602, P<0.05). The serum IL-17 was negatively correlated with IL-35 (r=-0.323, P<0.05), IL-17 was positively correlated with SIL-2R (r=0.429, P<0.05), IL-35 was negatively correlated with SIL-2R (r=-0.415, P<0.05). Conclusion: Serum IL-17, SIL-2R levels were significantly increased, IL-35 level was significantly decreased in the patients with thyroid cancer. which had significant effect for the early diagnosis and disease severity assessment of thyroid cancer.